Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

NCT03583385 | Completed Phase 1 Results

• 1 other identifier: MS200084_0015
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess bioequivalence between metformin hydrochloride (Glucophage® XR) manufactured in PT Merck Tbk, Indonesia (test drug) and metformin hydrochloride (Glucophage® XR) manufactured in Merck Santé, France (comparator drug) following single oral dose administration under fasting condition.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Maximum Observed Plasma Concentration (Cmax) of Metformin

  The maximum plasma concentration of Metformin.

  Pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin

  Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration.

  Pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

Secondary Outcomes (4)

• Area Under Plasma Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin

  Pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin

  Pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Terminal Elimination Half-life in Plasma (t½) of Metformin

  Pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

  Up to Day 51

Study Arms (2)

First Glucophage XR (Test), Then Glucophage XR (Comparator)

EXPERIMENTAL

Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.

Drug: Glucophage XR (Test drug); Drug: Glucophage XR (Comparator drug)

First Glucophage XR (Comparator), Then Glucophage XR (Test)

EXPERIMENTAL

Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.

Drug: Glucophage XR (Test drug); Drug: Glucophage XR (Comparator drug)

Interventions

Glucophage XR (Test drug) DRUG

Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.

Also known as: Metformin hydrochloride

First Glucophage XR (Comparator), Then Glucophage XR (Test); First Glucophage XR (Test), Then Glucophage XR (Comparator)

Glucophage XR (Comparator drug) DRUG

Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.

Also known as: Metformin hydrochloride

First Glucophage XR (Comparator), Then Glucophage XR (Test); First Glucophage XR (Test), Then Glucophage XR (Comparator)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants has provided written informed consent prior to the conduct of any study-related activities
• Body mass index of 18 to 25 kilogram per square meter (kg/m\^2)
• Good physical and mental health status, determined on the basis of medical history and physical examination
• Vital signs (blood pressure, pulse rate, respiratory rate and body temperature) in sitting position within the normal range or showing no clinically relevant deviation per the Investigator's opinion
• All values for laboratory assessments (hematology, clinical chemistry and urinalysis) within the normal range or showing no clinically relevant deviation per the Investigator's opinion
• No clinically significant abnormality on 12-lead electrocardiogram (ECG) recording as judged by the Investigator; corrected QT interval (QTc) (Bazett) should be less than equals to (\<=) 450 milliseconds (ms)
• Non-smoker or smoker less than 10 cigarettes per day
• Women of childbearing potential (WOCBP) who are not nursing, are not pregnant, and are using highly effective methods of birth control. Female participants may also be enrolled if they are postmenopausal or surgically sterilized/ hysterectomized at least 6 months prior to study participation
• WOCBP must have a negative urine pregnancy test at Screening and on each admission (Day 1 of each dosing period)
• Negative screen for alcohol and drugs abuse (opiate class, barbiturates, cocaine and metabolites, amphetamines, cannabinoids and benzodiazepines) at Screening and on each Study Check-In (Day -1 of each dosing period)
• Negative screen for Hepatitis B surface antigen (HBsAg), Hepatitis C Virus (HCV) antibodies and/or Human Immunodeficiency Virus (HIV) antibodies.

You may not qualify if:

• Participation in a clinical trial/study within 90 days prior to Screening
• Blood donation (equal or more than 300 milliliter \[mL\]) or significant blood loss within 90 days prior to first drug administration
• Any surgical or medical condition, including findings in the medical history or in the prestudy assessments, or any other significant disease, that in the opinion of the investigator, constitutes a risk or a contraindication for the participation of the participant in the study or that could interfere with the study objectives, conduct or evaluation
• History of malignant diseases, except in-situ basal cell skin tumors treated with curative intent
• History of surgery of the gastrointestinal tract which could influence the gastrointestinal absorption and/or motility per the Investigator's opinion
• History or presence of relevant liver diseases or hepatic dysfunction (laboratory result for liver function test greater than equals to (\>=) 1.5 upper limit of normal (ULN)
• History or presence of renal failure or renal dysfunction based on clinical symptoms and finding (serum creatinine concentration \>1.4 milligram per milliliter (mg/mL)
• Ascertained or presumptive hypersensitivity to the active drug substance and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
• Receipt of any prescription or non-prescription medication within 14 days before the first drug administration, except for hormonal contraceptives in female, and including multivitamins and herbal products (e.g. St John's Wort)
• Consumption of large quantities of methylxanthine-containing beverages (\> 5 cups of coffee/day or equivalent)
• Consumption of grapefruit, orange, cranberry or juices of these three fruits, 24 hours prior to drug administration
• Known lack of participant compliance or inability to communicate or cooperate with the Investigator (e.g., language problem, poor mental status)

Sponsors & Collaborators

• Merck KGaA, Darmstadt, Germany: lead

Study Sites (1)

PT Equilab International

Jakarta, 12430, Indonesia

Location

MeSH Terms

Interventions

Metformin; Drug Evaluation

Intervention Hierarchy (Ancestors)

Biguanides; Guanidines; Amidines; Organic Chemicals; Drug Development; Investigative Techniques; Evaluation Studies as Topic

Results Point of Contact

• Title: Communication Center
• Organization: Merck KGaA, Darmstadt, Germany

service@emdgroup.com

+49-6151-72-5200

Study Officials

• Medical Responsible

  PT Merck Tbk, Indonesia, and affiliate of Merck KGaA, Darmstadt, Germany

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 28, 2018
• First Posted: July 11, 2018
• Study Start: August 16, 2018
• Primary Completion: October 5, 2018
• Study Completion: October 5, 2018
• Last Updated: November 25, 2019
• Results First Posted: November 25, 2019

Record last verified: 2019-11

Locations

ID (1)